LONDON – Amal Therapeutics SA raised €21.2 million (US$23.8 million) in the second closing of its series B, enabling it to move forward with a phase I/II trial of its novel peptide vaccine, ATP-128, in combination with an anti-PD-1 checkpoint inhibitor.